{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:45:01Z","timestamp":1785890701483,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.022","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:20:54Z","timestamp":1777594854000},"page":"e942-e952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma and Impaired Renal Function"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-7009","authenticated-orcid":false,"given":"Ludek","family":"Pour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7523-7510","authenticated-orcid":false,"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3093-5248","authenticated-orcid":false,"given":"Wojciech","family":"Legiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-326X","authenticated-orcid":false,"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-1050","authenticated-orcid":false,"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Rymko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Najda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-3473","authenticated-orcid":false,"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Huledal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-9900","authenticated-orcid":false,"given":"Stefan","family":"Norin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2026.04.022_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.04.022_bib0002","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.04.022_bib0003","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12882-024-03717-5","article-title":"Kidney function in newly diagnosed myeloma patients: factors associated with kidney impairment and recovery","volume":"25","author":"Cesar","year":"2024","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.022_bib0004","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.022_bib0005","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2026.04.022_bib0006","doi-asserted-by":"crossref","first-page":"66641","DOI":"10.18632\/oncotarget.18420","article-title":"Melflufen - a peptidase-potentiated alkylating agent in clinical trials","volume":"8","author":"Wickstrom","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2026.04.022_bib0007","unstructured":"SmPC. Pepaxti. Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pepaxti-epar-product-information_en.pdf. Accessed on 15 Dec 2025."},{"key":"10.1016\/j.clml.2026.04.022_bib0008","unstructured":"EMA. The European Medicines Agency (EMA) Approves Melflufen (Pepaxti\u00ae) for the Treatment of Refractory Myeloma. \u200bhttps:\/\/www.mpeurope.org\/the-european-medicines-agency-ema-approves-melflufen-pepaxti-for-the-treatment-of-refractory-myeloma\/. Accessed on 15 Dec 2025."},{"issue":"2","key":"10.1016\/j.clml.2026.04.022_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jcph.2355","article-title":"Pharmacokinetics and metabolism of Melflufen, an alkylating peptide-drug conjugate, in patients with relapsed refractory multiple myeloma","volume":"64","author":"Huledal","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clml.2026.04.022_bib0010","unstructured":"IARC. IARC monographs on the evaluation of carcinogenic risks to humans. International Agency for Research on Cancer. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK304320\/. Accessed on 15 Dec 2025."},{"issue":"10","key":"10.1016\/j.clml.2026.04.022_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103120","article-title":"Melflufen: A peptide-drug conjugate for the treatment of multiple myeloma","volume":"9","author":"Mateos","year":"2020","journal-title":"J Clin Med."},{"key":"10.1016\/j.clml.2026.04.022_bib0012","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2026.04.022_bib0013","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.clml.2024.02.012","article-title":"PORT: A randomized, cross-over, phase 2 study of Melflufen peripheral versus Central intravenous administration in patients with relapsed\/refractory multiple myeloma","volume":"24","author":"Pour","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.clml.2026.04.022_bib0014","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and Dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.04.022_bib0015","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/bjh.17302","article-title":"Melflufen plus dexamethasone in relapsed\/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1","volume":"193","author":"Bringhen","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2026.04.022_bib0016","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.clml.2023.05.004","article-title":"Benefit versus risk assessment of Melflufen and Dexamethasone in relapsed\/refractory multiple myeloma: analyses from longer follow-up of the OCEAN and HORIZON studies","volume":"23","author":"Sonneveld","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2026.04.022_bib0017","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"69","author":"Nath","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2026.04.022_bib0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-017-0581-x","article-title":"Population pharmacokinetics and optimal sampling strategy for model-based precision dosing of Melphalan in patients undergoing hematopoietic stem cell transplantation","volume":"57","author":"Mizuno","year":"2018","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:46:58Z","timestamp":1785887218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001357"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma and Impaired Renal Function","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}